Sökning: "Lars-Åke Levin"
Visar resultat 11 - 15 av 16 avhandlingar innehållade orden Lars-Åke Levin.
11. The value of evaluating and implementing pharmaceuticals
Sammanfattning : Pharmaceuticals are a central part of high-quality health care and a resource for improving population health. However, high prices set by private companies who develop and own the rights to new pharmaceuticals question the value that they contribute to the health care system. LÄS MER
12. Health Technology Assessment of Assistance Dogs and Dog-Assisted Interventions
Sammanfattning : Dogs as an assistive aid for people with disabilities date as far back in time as the first century CE. Today, dogs are used in various settings to help and assist humans. ‘Assistance dogs’ is an umbrella term for guide dogs, hearing dogs and service dogs. LÄS MER
13. Effectiveness and costs of new medical technologies : register-based research in psoriasis
Sammanfattning : Psoriasis is a chronic, immunological and systemic disease with an estimated prevalence of about 2-3 percent. Psoriasis is associated with the joint disease psoriasis arthropathy. There are several treatments options available for psoriasis and patients with moderate to severe psoriasis generally need systemic agents. LÄS MER
14. Health economic aspects of emotional problems and pain symptoms in childhood and adolescence : Long-term outcomes, efficacy and cost-effectiveness of interventions
Sammanfattning : Emotional problems and pain symptoms among children and adolescents are a global public health challenge that imposes a great burden on the individuals affected and on society. Because resources are limited, allocation and prioritization are needed. Health economic analysis can constitute a foundation for such decisions. LÄS MER
15. Opportunity cost in healthcare priority setting
Sammanfattning : The resources available for the public provision of health care are not unlimited. Cost-effectiveness evidence on new healthcare interventions can help us prioritise in order to use scarce resources wisely, but to interpret cost-effectiveness evidence, it may appear as if we must make trade-offs between life and money. This is not so. LÄS MER